Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo by Schuster, K et al.
ORIGINAL ARTICLE
Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic
effects in vitro and in vivo
K Schuster
1, J Zheng
2,3, AA Arbini
4,5, CC Zhang
2,5 and PP Scaglioni
1
1Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center,
Dallas, TX, USA;
2Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA;
3Department
of Developmental Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA and
4Department of Pathology,
University of Texas Southwestern Medical Center, Dallas, TX, USA
The BCR/ABL tyrosine kinase promotes leukemogenesis
through activation of several targets that include the phospho-
inositide 3-kinase (PI3K). Tyrosine kinase inhibitors (TKIs),
which target BCR/ABL, induce striking clinical responses.
However, therapy with TKIs is associated with limitations such
as drug intolerance, inability to universally eradicate the
disease and emergence of BCR/ABL drug-resistant mutants.
To overcome these limitations, we tested whether inhibition of
the PI3K/target of rapamycin (mTOR) signaling pathway has
antileukemic effect in primary hematopoietic stem cells and
BA/F3 cells expressing the BCR/ABL oncoprotein. We deter-
mined that dual inhibition of PI3K/mTOR causes growth arrest
and apoptosis leading to profound antileukemic effects both
in vitro and in vivo. We also established that pharmacologic
inhibition of the mTORC1/mTORC2 complexes is sufﬁcient to
cause these antileukemic effects. Our results support the
development of inhibitors of the mTORC1/2 complexes for the
therapy of leukemias that either express BCR/ABL or display
deregulation of the PI3K/mTOR signaling pathway.
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Introduction
BCR/ABL is a constitutively active tyrosine kinase that promotes
leukemogenesis. Imatinib and other tyrosine-kinase inhibitors
(TKI) induce complete remissions in the vast majority of patients
with chronic myelogenous leukemia (CML) and exert signiﬁcant
antileukemic effects in patients with acute lymphoblastic
leukemia (ALL) expressing the BCR/ABL oncoprotein. However,
even though TKI therapy achieves long-term control of CML in
the majority of patients, it is believed that TKI therapy is not
sufﬁcient to eradicate leukemia. Moreover, therapy with TKIs is
associated with limitations such as drug intolerance and the
emergence of BCR/ABL drug-resistant mutants. In this regard, a
common cause of TKI resistance is due to point mutations in the
BCR/ABL kinase domain that preclude or hamper TKI binding.
Second generation TKI can overcome certain TKI-resistant
mutations except for the pan-resistant T315I.
1,2 These
shortcomings provide the rationale to develop improved
therapies for CML and ALL.
BCR/ABL promotes leukemogenesis through activation of
several oncogenic signaling pathways that include the phospho-
inositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin
(mTOR) signaling pathway.
1,3 The mTOR kinase is found in two
distinct complexes: mTORC1 and mTORC2. The S6 kinase
and the eukaryotic-initiation-factor 4E-binding protein-1 are
substrates of mTORC1, whereas AKT is a substrate of mTORC2.
4
The PI3K/AKT/mTOR signaling axis is a pivotal regulator of
leukemogenesis and of solid tumorigenesis.
5–7 As a result, the
PI3K/AKT/mTOR signaling pathway is a prime target for drug
development.
8,9
Rapamycin and its derivatives (rapalogs) are allosteric
inhibitors of mTORC1. These drugs are potent immunosuppres-
sors, but they have demonstrated limited anticancer activity in
patients.
10,11 This is most likely due to the fact that rapamycin
and RAD001 inhibit only one of the several downstream targets
of PI3K leaving AKT unaffected. Moreover, they also disrupt a
feedback mechanism that dampens PI3K activity leading to a
compensatory upregulation of AKT activity, causing counter-
productive prosurvival effects.
11,12 On the contrary, ATP-
competitive dual PI3K/mTORC1/2 and mTORC1/2 inhibitors
display potent anticancer properties both in vitro and in vivo in
a wide range of malignant cells including leukemia. Several of
these compounds are being tested in preclinical models.
8,9,13–16
Thus, we tested the antileukemic effects of PI3K signaling
pathway inhibitors in primary murine CML samples and in
BA/F3 cells, a murine pro-B cell line that recapitulates the effects
of wild-type and TKI-resistant BCR/ABL in leukemic disease.
Materials and methods
Cell studies
BA/F3 cells expressing empty vector (control), BCR/ABL wild-
type or imatinib-resistant mutations (BCR/ABL E255K and T315I)
were a kind gift of Dr Brian Druker (Oregon Health Science
University, Portland, OR, USA) and maintained as described.
17
Growth curves were performed in triplicate and the cell number
was determined after 72h. Primary bone marrow cells were
isolated from healthy or CML leukemic adult C57/B6 mice. To
generate CML mice, we isolated E15.5 fetal liver Lin
 cells by
AutoMACS (Auburn, CA, USA) and performed spin inoculation
with MSCV-BCR/ABL-IRES-GFP retroviral supernatant in a
medium containing 10% fetal bovine serum, 20ng/ml stem cell
factor, 20ng/ml interleukin-3 and 10ng/ml interleukin-6 with
5mg/ml polybrene. Infected cells were then transplanted into
lethally irradiated (1000rad) C57BL/6 mice by retro-orbital Received 4 March 2011; revised 3 May 2011; accepted 8 June 2011
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www.nature.com/bcjinjection. Primary murine bone marrow colonies were grown in
MethoCult GM (Stem cell Technologies, Vancouver, BC,
Canada) supplemented with the indicated drug dosage in
duplicate and counted after 7 days in culture.
Inhibitors
BEZ235, KU-0063794 and GDC0941 were from Chemdea
(Ridgewood, NJ, USA);
18–20 rapamycin was from Invitrogen
(Carlsbad, CA, USA). AZD8055 and ARRY142886 were from
Chemitek (Indianapolis, IN, USA).
21,22 Inhibitors were added to
mid-log-phase cell cultures at the indicated concentrations. The
concentration for rapamycin was 100nM. Control cells were
incubated with a medium containing a solvent (dimethyl
sulfoxide) at a concentration corresponding to the highest dose
used in inhibitor-treated cells. For western blot analysis, cells
were incubated with the inhibitor for 48h. In vivo, BEZ235 was
administered by gavage daily in N-methyl-2-pyrrolidone (NMP)/
PEG300 (10:90, v/v), control mice received PEG300 containing
10% NMP.
18
Determination of apoptosis
Cell cycle analysis and determination of apoptosis by propidium
iodide staining were done following a standard procedure with a
FC500 Beckman Coulter ﬂow cytometer (Brea, CA, USA) using
the WinMDI V2.8. software (Purdue University Cytometry
Laboratories, West Lafayette, IN, USA).
23,24 We assessed
apoptosis also by determining caspase activity (Promega
Caspase-Glo 3/7 assay, Madison, WI, USA). Following the
manufacturer’s protocol, we measured relative luminescence as
a ratio between treated and untreated cells. The ratio was
calculated as follows: luminescence was measured and sub-
tracted from a background control. Values were normalized to
the number of cells in each well. The ratio was calculated
between treated and untreated sample. We used, staurosporine,
a well-known inducer of apoptosis, as a positive control at the
indicated concentrations and time points.
For determination of apoptosis in vivo, we used the Tunel
assay ApopTag Plus Peroxidase in situ Apoptosis Detection Kit
(Millipore, Billerica, MA, USA). Bright ﬁeld images of spleen
sections were taken with a Leica Inverted Microscope DMI6000
at a magniﬁcation of 200.
Immunoblotting and immunohistochemistry
Western blotting and immunohistochemical studies were done
as described previously.
24 The following antibodies were
obtained from Cell Signaling Technologies (Danvers, MA,
USA): AKT, Ser473 phospho-AKT, Ser235/236 phospho-S6, S6,
phospho-ERK, ERK, 4-EBP1 and phospho-4EBP1. Tubulin and
HSP-90 were from Sigma-Aldrich (St Louis, MO, USA).
Mouse studies
BA/F3 (110
6) cells expressing mutant BCR/ABL T315I were
delivered by tail vein injection in NOD-SCID-IL2gKO. We
assessed tumor burden by counting blasts in blood smears and
spleen sections. These studies were performed according to the
guidelines of the UT Southwestern Institutional Animal Care and
Use Committee.
Statistical analyses
All data presented are representatives of experiments repeated at
least twice or more with equivalent results. Signiﬁcance was
determined using t-test analysis or one-way analysis of variance
(Holm–Sidak method) utilizing the SigmaPlot software (Systat
Software Inc., San Jose, CA, USA).
Kern’s method was used to evaluate synergistic effects
in vitro.
25 In brief, the expected cell number for dual treatment
was deﬁned as product of the percentages of remaining cells
treated with drug A or B divided by 100. A ratio was calculated
by dividing the expected cell number by the observed cell
number. A ratio of 1 was termed additive, whereas a ratio larger
than 1 or smaller than 1 was termed synergistic or antagonistic,
respectively.
Results
Dual PI3K/mTORC1/2 blockade with BEZ235 leads to a
striking antiproliferative effect in primary murine CML
samples
To begin testing the antileukemic effects of inhibitors of the PI3K
signaling pathway we performed methylcellulose colony assays
with primary murine CML cells obtained from mice that
underwent bone marrow reconstitution with hematopoietic
cells transduced with a retroviral vector-expressing BCR/ABL.
For these studies we used BEZ235, a dual PI3K/mTORC1/2
inhibitor, GDC0941, a pan-PI3K inhibitor and KU-0063794, a
dual mTORC1/2 inhibitor.
18–20 We found that all three
compounds fully suppressed colony formation of primary
murine CML samples to an equivalent degree (Figure 1a).
Notably, wild-type hematopoietic cells were less sensitive to the
antiproliferative effects exerted by BEZ235, GDC0941 and
KU-0063794 (Figure 1a).
Inhibition of the PI3K signaling pathway leads to a
striking antiproliferative effect in BA/F3 cells expressing
wild-type and imatinib-resistant BCR/ABL mutants
We used BA/F3 cells to better characterize the antileukemic
effects we observed in primary CML cells. We determined
that BEZ235 strikingly inhibits proliferation of cells expressing
BCR/ABL and imatinib-resistant mutants (Figure 1b), whereas
rapamycin not only had a modest effect on cell proliferation, but
also showed little selectivity toward BCR/ABL-expressing cells
(Figure 1c). Notably, parental BA/F3 cells were signiﬁcantly less
sensitive to BEZ235 treatment than cells expressing BCR/ABL
(Figure 1b). As expected, imatinib did not affect proliferation of
BA/F3 cells expressing mutant BCR/ABL (Figure 1d). These
antiproliferative effects correlate with the ability of BEZ235 to
inhibit mTORC1/2 signaling in these cells as determined by
phospho-4EBP1 (T37/46), phospho-S6 (Figure 1e), which are
downstream targets of mTORC1, and phospho-AKT (T473), a
target of mTORC2 (Figures 1f and g). We also determined that
phospho-ERK was upregulated by BEZ235 in BA/F3 cells
expressing BCR–ABL, most likely due to a compensatory
feedback mechanism (Figure 1e).
11,26 Furthermore, we con-
ﬁrmed that inhibition of PI3K with GDC0941, and mTOR with
KU-0063794 and AZD8055, but not of MEK1 with
ARRY142886, appropriately suppressed phosphorylation of
AKT S473 (Figures 1f and g), independently of BCR–ABL
expression.
Dual PI3K/mTORC1/2 blockade induces cell death
in BA/F3 cells
To better characterize the antiproliferative effect of dual PI3K/
mTOR blockade we analyzed BA/F3 cells treated with BEZ235
by ﬂow cytometry. For these experiments, we used BEZ235 at a
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Blood Cancer Journalconcentration of 150nM, which signiﬁcantly inhibits the growth
of BA/F3 cells expressing BCR/ABL. We determined that BEZ235
induced a striking increase of the percentage of cells present in
the sub-G0 phase of the cell cycle, which represents cells
undergoing apoptosis (Figures 2a and b). The percentage
increase in the sub-G0 cell population was signiﬁcantly more
evident in BA/F3 cells expressing wild-type and BCR/ABL
mutants resistant to TKI (Figure 2b). To conﬁrm with an
unrelated assay that BEZ235-treated cells undergo apoptosis,
we measured cleaved caspase 3, a well-known marker of
apoptosis. Indeed, we found that BEZ235 promoted a twofold
increase of caspase 3 activation in a time- and dose-dependent
manner (Figures 2c and d). Taken together these experiments
indicate that dual PI3K/mTOR blockade leads to apoptosis of
BA/F3 cells expressing wild-type and TKI-resistant BCR/ABL.
Pharmacologic inhibition of mTORC1/2 recapitulates
the effects of dual PI3K/mTORC1/2 blockade in
BCR/ABL-expressing cells
We sought to determine whether the antileukemic effect exerted
in vitro by BEZ235 is due to inhibition of the PI3K, mTORC1 or
Figure 1 Dual PI3K/mTORC1/2 blockade inhibits proliferation of primary CML cultures and of BA/F3 cells expressing BCR–ABL. (a) Histogram of
primary murine hematopoietic stem cell cultures obtained from wild-type (BM wt) and primary CML murine bone marrow (BM BCR–ABL) treated
as indicated. Relative colony formation was calculated as percentage between treated and untreated cells and shown on the y axis. (b) Proliferation
assay of BA/F3 cells expressing vector control (control), wild-type BCR–ABL (wt) or BCR–ABL mutants (T315I) treated with BEZ235 (BEZ). Note that
BEZ235 causes inhibition of proliferation in a dose-dependent manner in BCR/ABL-expressing cells. (c) Growth curve of the indicated BA/F3 cells
treated with increasing doses of the mTORC1 inhibitor rapamycin for 72h. (d) Representative growth curve of the indicated BA/F3 cells treated
with imatinib (Imat.) for 72h. (e) BA/F3 control, wt and T315I cells treated with BEZ235 at the indicated concentrations for 24h. We detected total
and phosphorylated (p-) proteins by western blot. BEZ235 decreases phosphorylation of S6 and 4EBP1 and upregulates p-ERK. (f, g) BA/F3 cells
expressing control (g) or wild-type BCR/ABL (f) were treated with 1mMImat inib (Imat.), 10mMGDC0941 (GDC), 1.5mMKU-0067394 (KU), 100nM
AZD8055 (AZD), 100nM BEZ235, 5mM ARRY142886 (ARRY) or 100nM insulin. TORC2 activity was determined by western blot of phospho-AKT
S473. The drugs inhibited their intended targets within 1h of treatment.
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KU-0063794 and its derivative AZD8055, small molecules that
target speciﬁcally the mTORC1 and mTORC2 protein
complexes and GDC0941, a speciﬁc pan-PI3K inhibitor.
19–21
We determined that mTORC1/2 inhibition with KU-0063794 or
AZD8055 strikingly reduces cell proliferation in BA/F3 cells
Figure 2 Dual PI3K/mTORC1/2 inhibition with BEZ235 induces apoptosis in BA/F3 cells expressing BCR–ABL. (a) Cell cycle analysis of BA/F3
control, wild-type (wt) BCR/ABL and T315I untreated (UT) and treated with BEZ235 at 150nM for 48h. Note that treatment with BEZ235 causes a
signiﬁcant increase in the Sub-G0 fraction of the cell cycle in cells expressing BCR/ABL indicating apoptotic response. (b) Fold change analysis
histograms of BA/F3 control, wt BCR–ABL and mutant T315I treated with BEZ235 of three individual ﬂow cytometry experiments. In brief,
percentages of each cell cycle faction were averaged. Fold change was calculated by normalizing to the percentage of untreated cells. Standard
deviations were calculated and are shown as error bars. Cells were treated with 150nM of BEZ235 for 48h. (c, d) Graphs show activation of
caspase 3 and 7 upon BEZ235 treatment in BA/F3 cells expressing wild-type BCR/ABL in a dose- (c) and time- (d) dependent manner. Cells were
treated as indicated and apoptosis was measured by luminescence with the Caspase-Glo 3/7 assay kit. Luminescence was normalized to cells
present in each sample and presented as relative value. Staurosporine was used as positive control to detect caspase activation upon apoptotic
stimuli. Vertical lines indicate standard deviations in all graphs presented.
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over, we found that parental BA/F3 cells were signiﬁcantly less
sensitive to the effects of both of these inhibitors than cells
expressing BCR/ABL (Figures 3a and b, respectively). We also
determined that the GDC0941 effectively decreases cell
proliferation, however, this drug did not show a selective effect
based on BCR/ABL expression in BA/F3 cells (Figure 3c).
We conﬁrmed by western blot analysis that KU-0063794 and
GDC0941 inhibit targets downstream of the mTORC1 complex
such as p-S6 (Figures 3d and e, respectively) in both parental
BA/F3 and cells expressing BCR–ABL. These ﬁndings suggest
that GDC0941 may lack therapeutic index in leukemic cells.
Thus, we conclude that dual inhibition of the mTORC1/2
complexes is a more desirable therapeutic strategy to affect
oncogenic signaling downstream of BCR/ABL.
Dual PI3K/mTORC1/2 inhibition with BEZ235 in a
mouse model of CML
Others and we have used BEZ235 in mouse models of cancer
due to its excellent bioavailability and have demonstrated
signiﬁcant antitumor effects.
18,24 Moreover, this drug has been
already tested in phase I clinical trials and is presently tested in
phase II clinical trials for other human cancer types.
9 Thus, our
in vitro data prompted us to test the antileukemic properties of
BEZ235 in vivo. For this purpose, we injected NOD-SCID-
IL2gKO mice intravenously with BA/F3 cells expressing the pan-
TKI-resistant BCR/ABL T315I mutant. In this mouse model, mice
invariably succumb to a CML-like disease in about 3 weeks.
27
Two cohorts of ﬁve leukemic mice each, received treatment
with BEZ235 or vehicle 14 days after injection. We killed mice
of both cohorts after 4 days of treatment and measured spleen
Figure 3 Inhibition of the mTORC1/2 complex recapitulates the effects of BEZ235 treatment in BA/F3 cells. (a) Growth curve of BA/F3 control,
wild type (wt), E255K and T315I cells treated with increasing doses of mTOR inhibitor KU-0067394 (KU) for 72h. Note that KU-0063794 causes
inhibition of cell proliferation preferentially in BCR–ABL-expressing cells. (b) Growth curve of BA/F3 control, wt and T315I cells treated with
increasing doses of mTOR inhibitor AZD8055 (AZD) for 72h. Note that AZD8055 also causes inhibition of cell proliferation preferentially in BCR–
ABL-expressing cells. (c) Growth curve of BA/F3 control, wt, E255K and T315I cells treated with increasing doses of PI3K inhibitor GDC0941
(GDC) for 72h. (d, e) Western blot analysis of BA/F3 cells treated with KU-0063794 or GDC0941, respectively. Detected proteins are indicated on
the left. Note that both drugs decreased phosphorylation of S6 ribosomal protein, a downstream target of TORC1. Densitometry analysis was
performed using ImageJ software, Research Services Branch, NIH (rsbweb.nih.gov). Level of phosphorylation of S6 protein was calculated as a
ratio to total S6 protein. The resulting ratios were normalized to the level of untreated cells of each cell line. (f) Western blot of BA/F3 BCR/ABL wt
cells untreated (UT) and treated with 1mMimatinib (Imat.), 10mMGDC0941, 1.5mMKU-0067394 and 100nMAZD8055 (AZD). Note that both, KU
and AZD, upregulated p-ERK and downregulated the activity of the TORC1 target 4-EBP1. Vertical lines indicate standard deviations in all graphs
presented.
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to quantify response to treatment. We determined that BEZ235
caused a signiﬁcant reduction in leukemic burden (Figure 4a).
All leukemic animals showed extramedullary hematopoiesis in
their spleens (Figure 4b panel B1) as compared with control
animals (Figure 4b panel A1). On the contrary, spleens of
untreated animals were packed with leukemic cells with
abundant mitotic ﬁgures (Figure 4b, panel B1). Spleens of mice
treated with BEZ235 showed nuclear fragmentation suggesting
the presence of apoptotic cells (Figure 4b panel E1). In addition,
the spleens of two treated animals contained neutrophil clusters,
a sign of an inﬂammatory response, and one spleen showed
extensive necrosis (Figure 4b panels C1 and D1, respectively).
Terminal transferase dUTP nick-end labeling staining conﬁrmed
an increase in DNA fragmentation of leukemic cells consistent
with an apoptotic response in treated animals (Figure 4b,
panel H1). These data show that dual PI3K/mTOR blockade with
BEZ235 induces a striking antileukemic effect both in vitro and
in vivo.
Discussion
The treatment modalities of CML have been revolutionized by
the availability of TKIs that speciﬁcally target the BCR/ABL
oncogene. Such therapies lead a 10-year survival that
approaches 90% in newly diagnosed patients. Nevertheless this
form of therapy is hampered by several limitations. For example,
patients with advanced CML are less sensitive to TKI therapy and
responses are short lived. Moreover, drug resistance due to the
emergence of TKI-resistant mutants is signiﬁcant in advanced
phase CML patients. Second generation TKIs can over-ride
some, but not all imatinib-resistant mutants.
1 Finally, it is
believed that TKI therapy should be continued indeﬁnitely in
responding patients due to the inability of these drugs to
eradicate CML. Thus, innovative treatment modalities are
needed to improve the outcome of CML even further, for
example, by over-riding TKI-resistant mutants, or to promote
eradication of BCR/ABL-harboring cells in patients that respond
to TKI therapy. BA/F3 used in this study grow independently of
interleukin-3 when expressing the BCR/ABL oncoprotein and
have been previously demonstrated to recapitulate not only the
events leading to BCR/ABL-induced leukemogenesis but also the
therapeutic effects of TKIs.
17
The BCR/ABL oncogene has a pivotal role in leukemogenesis
by activating several oncogenic signaling pathways. Among
these, the PI3K/mTORC1/2 network has been under intense
investigation for the pivotal role that it has in regulating cell
proliferation, survival and metabolism.
4,5 As a result PI3K,
mTORC1/2 or dual PI3K/mTORC1/2 inhibitors have been
developed with the expectation that these drugs would elicit
potent antitumor effects.
Our study supports the clinical development of mTORC1/2
inhibitors for the treatment of leukemias expressing BCR/ABL as
well as TKI-resistant BCR/ABL mutants including the pan-
resistant T315I mutant. We observed that KU-0063794 exerts
antiproliferative effects at a dosage comparable to previous
studies conducted in cells exposed to cytokines and growth
factors.
19 Moreover, our observation that its derivative
AZD8055 elicits comparable antileukemic effects in vitro
suggests that the mTORC1/2 complexes are critical therapeutic
targets in BCR/ABL-induced disease, which was previously
placed downstream of PI3K in CML cells.
28 These observations
provide a rationale to explain the failure of rapamycin, which
targets only mTORC1, to produce profound antileukemic effects
in vivo. We found surprising that GDC0941 affected the
parental BA/F3 with similar efﬁcacy as compared with BA/F3
cells expressing BCR/ABL. This could be caused by off target or
mTORC1/2-independent drug effects such as the ability of BCR/
ABL to induce ROS activity through PI3K.
29 The mechanistic
underpinnings of this divergent effect should be investigated in
future studies. Based on these considerations, we propose that
Figure 4 Dual PI3K/mTOR inhibition with BEZ235 induces antileukemic effects in vivo.( a) Histogram demonstrating the weights of spleens
obtained from mice injected with BA/F3 BCR/ABL T315I cells. Mice received BEZ235 or its diluent by gavage. Animals were killed after 4 days of
treatment. Compared with untreated leukemic mice, spleens from treated mice displayed dramatic weight reduction. Vertical lines indicate
standard deviations. (b; A1–H1) Hematoxylin and eosin staining of representative spleen sections (200 magniﬁcations). Spleens were obtained
from (A1) leukemia-free, (B1) untreated leukemic and (C1–H1) leukemic mice treated with BEZ235. Histologic changes in spleens from treated
mice included (C1) neutrophil clusters, (D1) necrosis and (E1) condensed apoptotic nuclei (indicated by asterisk and inlay). Terminal transferase
dUTP nick-end labeling staining (F1–H1) was performed using the Apo Tag peroxidase in situ apoptosis detection kit (Millipore, Billerica, MA,
USA). (F1) Negative control section, (G1) untreated leukemic spleen, (H1) leukemic spleen after therapy. Cells positive for DNA fragmentation
appear brown as indicated by asterisk and inlay.
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BCR/ABL-expressing leukemias.
These data conﬁrm and extend several in vivo studies with
pan-PI3K/mTORC1/2 or mTORC1/2 inhibitors. So far, this class
of drugs has been tested mostly in cellular and preclinical
models of solid malignancies.
8,9 In this setting, PI3K/mTOR
inhibition leads to antiproliferative or proapoptotic effects
depending on cellular context.
24,30,31 More recently, these
drugs have demonstrated activity in lymphoma, acute leukemias
and myeloma cells.
16,32-34 In hematopoietic malignancies
inhibition of the PI3K/mTOR signaling pathway has been mostly
associated with pro-apoptotic effects. This observation suggests
that PI3K/mTORC1/2 inhibitors will be valuable anticancer
drugs in a wide spectrum of neoplastic diseases.
Notably, we have not noticed overt toxicities or effects on
blood counts during BEZ235 administration in vivo (data not
shown). These results are in agreement with the experience of
others and us with murine mouse models.
24,31,34 Future studies
should determine whether mTORC1/2 inhibitors provide advan-
tages over pan-PI3K/mTORC1/2 inhibitors. In this regards, it was
recently shown that pan-PI3K/mTORC inhibitors cause greater
immunosuppression than TORC1/2 inhibitors in mouse models.
34
We observed an increase in phosphorylation of ERK, when
treating cells with BEZ235 suggesting a feedback mechanism to
overcome PI3K and mTORC1/2 blockade. As the activation of
other survival signaling pathways could be detrimental in the
treatment of CML, we analyzed the combination therapy of
BEZ235 with ARRY142886, a MEK1/2 inhibitor (Supplementary
Figure 1a). However, dual treatment with BEZ235 did not
increase the antitumorigenic effects observed with either drug
alone. It will be of interest to determine whether combination
therapy with inhibitors of mTORC1/2 and other targets of BCR/
ABL such as SRC and JNK will be beneﬁcial.
1
Others and we have reported that dual PI3K/mTORC1/2
blockade and DNA damage synergize to induce apoptosis.
18,24
Thus, we tested cytarabine, an antimetabolite commonly used in
the treatment of acute leukemias. Unexpectedly, we found, that
the combination of cytarabine with BEZ235 led to an
antagonistic effect on the growth of leukemic BA/F3 cells
(Supplementary Figures 1c and d); whereas it had a neutral
effect on the parental BA/F3 cells (Supplementary Figure 1e).
These data suggest that combination regimens of PI3K/mTOR
inhibitors with antimetabolites or DNA-damaging agents may
lead to unintended consequences in leukemias.
Taken together, our ﬁndings provide the rationale for the
development of selective mTOR inhibitors for the treatment of
leukemias expressing BCR/ABL and other malignancies that
depend on the mTORC1/2 complex.
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